TY - JOUR
T1 - The Influence of Some Axial Ligands on Ruthenium–Phthalocyanine Complexes
T2 - Chemical, Photochemical, and Photobiological Properties
AU - Martins, Tássia Joi
AU - Negri, Laisa Bonafim
AU - Pernomian, Laena
AU - Faial, Kelson do Carmo Freitas
AU - Xue, Congcong
AU - Akhimie, Regina N.
AU - Hamblin, Michael R.
AU - Turro, Claudia
AU - da Silva, Roberto S.
N1 - Publisher Copyright:
© Copyright © 2021 Martins, Negri, Pernomian, Faial, Xue, Akhimie,Hamblin, Turro and da Silva.
PY - 2021/1/12
Y1 - 2021/1/12
N2 - This work presents a new procedure to synthesize ruthenium–phthalocyanine complexes and uses diverse spectroscopic techniques to characterize trans-[RuCl(Pc)DMSO] (I) (Pc = phthalocyanine) and trans-[Ru(Pc)(4-ampy)2] (II) (4-ampy = 4-aminopyridine). The triplet excited-state lifetimes of (I) measured by nanosecond transient absorption showed that two processes occurred, one around 15 ns and the other around 3.8 μs. Axial ligands seemed to affect the singlet oxygen quantum yield. Yields of 0.62 and 0.14 were achieved for (I) and (II), respectively. The lower value obtained for (II) probably resulted from secondary reactions of singlet oxygen in the presence of the ruthenium complex. We also investigate how axial ligands in the ruthenium–phthalocyanine complexes affect their photo-bioactivity in B16F10 murine melanoma cells. In the case of (I) at 1 μmol/L, photosensitization with 5.95 J/cm2 provided B16F10 cell viability of 6%, showing that (I) was more active than (II) at the same concentration. Furthermore, (II) was detected intracellularly in B16F10 cell extracts. The behavior of the evaluated ruthenium–phthalocyanine complexes point to the potential use of (I) as a metal-based drug in clinical therapy. Changes in axial ligands can modulate the photosensitizer activity of the ruthenium phthalocyanine complexes.
AB - This work presents a new procedure to synthesize ruthenium–phthalocyanine complexes and uses diverse spectroscopic techniques to characterize trans-[RuCl(Pc)DMSO] (I) (Pc = phthalocyanine) and trans-[Ru(Pc)(4-ampy)2] (II) (4-ampy = 4-aminopyridine). The triplet excited-state lifetimes of (I) measured by nanosecond transient absorption showed that two processes occurred, one around 15 ns and the other around 3.8 μs. Axial ligands seemed to affect the singlet oxygen quantum yield. Yields of 0.62 and 0.14 were achieved for (I) and (II), respectively. The lower value obtained for (II) probably resulted from secondary reactions of singlet oxygen in the presence of the ruthenium complex. We also investigate how axial ligands in the ruthenium–phthalocyanine complexes affect their photo-bioactivity in B16F10 murine melanoma cells. In the case of (I) at 1 μmol/L, photosensitization with 5.95 J/cm2 provided B16F10 cell viability of 6%, showing that (I) was more active than (II) at the same concentration. Furthermore, (II) was detected intracellularly in B16F10 cell extracts. The behavior of the evaluated ruthenium–phthalocyanine complexes point to the potential use of (I) as a metal-based drug in clinical therapy. Changes in axial ligands can modulate the photosensitizer activity of the ruthenium phthalocyanine complexes.
KW - B16F10 murine melanoma cells
KW - cell viability
KW - photobiological assays
KW - photodynamic therapy
KW - ruthenium-phthalocyanine complexes
UR - http://www.scopus.com/inward/record.url?scp=85100051270&partnerID=8YFLogxK
U2 - 10.3389/fmolb.2020.595830
DO - 10.3389/fmolb.2020.595830
M3 - Article
AN - SCOPUS:85100051270
SN - 2296-889X
VL - 7
JO - Frontiers in Molecular Biosciences
JF - Frontiers in Molecular Biosciences
M1 - 595830
ER -
